{"id":"W4281945717","doi":"10.1200/jco.2022.40.16_suppl.tps8069","title":"CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pomalidomide; Medicine; Daratumumab; Tolerability; Multiple myeloma; Lenalidomide; Carfilzomib; Internal medicine; Pharmacodynamics; Bortezomib; Pharmacokinetics; Refractory (planetary science); Pharmacology; Oncology; Phases of clinical research; Clinical trial; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009587136,0.0008608752,0.00123375,0.0003995814,0.0002475827,0.001096026,0.0008169552,0.001028419,0.006499837],"category_scores_gemma":[0.00107358,0.0004112817,0.001204962,0.0003731516,0.0005095228,0.0007803459,0.0003042398,0.002916213,0.001268767],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009875044,"about_ca_system_score_gemma":0.0009360443,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008354142,"about_ca_topic_score_gemma":0.002058145,"domain_scores_codex":[0.9997806,0.00009023765,0.000008006351,0.00004464375,0.00002641616,0.00005007784],"domain_scores_gemma":[0.9996657,0.00006058734,0.00008256145,0.00002343414,0.00002252178,0.0001450968],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5623177,0.0441779,0.009178448,0.002413006,0.002974165,0.0004254766,0.0004292036,0.004052741,0.06331158,0.001523102,0.01837005,0.2908266],"study_design_scores_gemma":[0.6359944,0.3279724,0.014714,0.0001970445,0.000891888,0.0008560358,0.0001278371,0.002730802,0.003925058,0.0008828235,0.01165423,0.00005344053],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762667,0.01098251,0.0007464227,0.001654886,0.0003447642,0.002307574,0.00237485,0.0002553693,0.00506701],"genre_scores_gemma":[0.9802399,0.00450132,0.001579694,0.002306879,0.0001814599,0.002094159,0.004151317,0.00004232249,0.004902983],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006499837,"threshold_uncertainty_score":0.02174407,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1685095355494466,"score_gpt":0.5046144150094214,"score_spread":0.3361048794599747,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}